Testing FCN-159 for Brain AVM
Treatments studied
Part of Brain & nervous system clinical trials.
This trial tests an oral medication called FCN-159 for people with a high-grade brain AVM that has never bled. The goal is to see if it can shrink the AVM or prevent future problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old.
- You have a brain AVM that has not bled.
- You have not had radiation, surgery, or medication for your AVM before.
- You do not have certain genetic conditions like HHT or CM-AVM syndrome.
- You are able to swallow pills, have good kidney and liver function, and are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at outcomes for people with an unruptured brain arteriovenous malformation (AVM) using medical care only, without procedures. It may help doctors understand which medical approach and monitoring works best for different AVM locations seen on CT scans.
This trial tests if injecting a medication called bevacizumab directly into certain hard-to-treat brain blood vessel malformations can help. It is for adults with large or complex malformations that have already bled or caused serious symptoms and cannot be removed with standard surgery or procedures.
This study collects medical and imaging information from people with a brain arteriovenous malformation (AVM) to understand how different treatments are used in real life. It may help doctors improve future care, even if you are not receiving a new drug in this study.
This study tests emergency surgery for patients with bleeding from a brain blood vessel malformation (AVM). It aims to see if urgent surgery can help people with this type of stroke.
This study looks at how to best treat people with untreated cerebral cavernous malformations (a cluster of abnormal blood vessels in the brain). It compares outcomes between those who have surgery and those who are monitored with regular check-ups, and will follow participants for a long time to see how they do.
This trial tests a liquid embolic agent (a gel-like material) injected into the blood vessels of a brain arteriovenous malformation (AVM) to block abnormal blood flow. It’s for people aged 18 to 80 with certain types of AVMs that doctors think can be treated this way.
Hear when a new Brain Arteriovenous Malformations trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.